Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
Public Ventures Discovery Day |
||
Date: |
|
|
Presentation: |
|
|
Location: |
|
A video replay of the fireside chat will be available shortly after the conclusion of the event on the Company’s investor relations website on the Events & Presentations page.
Discovery Day is a unique event for investors to learn about a curated group of venture-stage, deep-tech companies; share feedback and questions with company leaders; and connect with like-minded investors.
To register for Discovery Day, please email community@publicventures.com. Please note that spots are limited, and attendance preference will be given to existing MDBH shareholders.
About
Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.
Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318730778/en/
Investor & Media Contact:
Chief Legal Officer
1-866-292-4601
irteam@cybin.com – or – media@cybin.com
Source: